Monitoring Agency Report

SG Finserve Limited Date: July 14, 2026 Secretary National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, BSE Limited Plot No. C/1, G Block, Department of Corporate Services Bandra – Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Dalal Street, Mumbai-400001 Mumbai – 400 051 BSE Scrip Code: 539199 NSE Symbol: SGFIN Dear Sir/Madam, Sub: Monitoring Agency Report under Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we have enclosed herewith the Monitoring Agency Report for the quarter ended June 30, 2026, issued by CARE Ratings Limited, Monitoring Agency, appointed to monitor the utilization of proceeds of Preferential Issue. The aforesaid report duly reviewed and approved by Audit Committee and Board of Director in their meetings held on July 14, 2026, is attached as Annexure. The same is also available on the website of company i.e. www.sgfinserve.com Kindly take the same in your record. Thanking you For SG Finserve Limited Kush Mishra Company Secretary & Compliance Officer SG Finserve Limited (CIN: L64990DL1994PLC057941) Regd. Office: 37, Hargobind Enclave, Vikas Marg, East Delhi, Delhi-110092, Ph.: 0120-4041 400 Corporate Office: - 35-36 Kaushambi, Near Anand Vihar Terminal, Ghaziabad, Uttar Pradesh - 201010 E-mail: info@sgfinserve.com, Website: www.sgfinserve.com No. CARE/NRO/GEN/2026-27/1063 The Board of Directors SG Finserve Limited 37, Hargobind Enclave, Vikas Marg Delhi, 110092, India July 14, 2026 Dear Sir/Ma’am, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to Preferential Issue of SG Finserve Limited (“the Company”) We write in our capacity of Monitoring Agency for the preferential issue for the amount aggregating to ₹450.00 crore of the Company and refer to our duties cast under Regulation 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations. In this connection, we are enclosing the Monitoring Agency Report for the quarter ending June 30, 2026, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated September 04, 2024. Request you to kindly take the same on records. Thanking you, Yours faithfully, Mr Jitendra Meghrajani Associate Director Jitendra.Meghrajani@careedge.in CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in • www.careedge.in CIN-L67190MH1993PLC071691 Report of the Monitoring Agency Name of the issuer: SG Finserve Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: Nil (b) Range of Deviation: Nil Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Jitendra Meghrajani Designation of Authorized person/Signing Authority: Associate Director CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in • www.careedge.in CIN-L67190MH1993PLC071691 1) Issuer Details: Name of the issuer : SG Finserve Limited Name of the promoter : Mr. Rahul Gupta and Mr. Rohan Gupta Industry/sector to which it belongs : Non-Banking Financial Company 2) Issue Details Issue Period : 18 months from the date of allotment Type of issue (public/rights) : Preferential issue of Warrants Type of specified securities : Warrants convertible into equity shares IPO Grading, if any : Not applicable Issue size (in crore) : 450.00 crore 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information / certifications considered by Comments of the Comments of the Particulars Reply Monitoring Agency for preparation Monitoring Agency Board of Directors of report ₹21.19 crore has been received No Comments against the warrants in Q1FY27, of Whether all utilization is as per the disclosures in the Offer CA certificate*, management certificate, which ₹11.19 crore has been Document? bank statements, sample invoices utilized for working capital requirements and ₹10 crore for general corporate purposes. Whether shareholder approval has been obtained in case of No Comments No material deviation observed material deviations from expenditures disclosed in the Offer Not applicable CA certificate*, management certificate from objects in offer document Document? Whether the means of finance for the disclosed objects of No Comments No CA certificate*, management certificate No comments the issue have changed? No, there are no deviations No Comments Is there any major deviation observed over the earlier No Previous monitoring agency report observed from the last monitoring monitoring agency reports? agency report Whether all Government/statutory approvals related to the No Comments Not applicable CA certificate*, management certificate No comments object(s) have been obtained? Whether all arrangements pertaining to technical No Comments Not applicable CA certificate*, management certificate No comments assistance/collaboration are in operation? Are there any favorable/unfavorable events affecting the No CA certificate*, management certificate No comments No Comments CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar [Showing first 8,000 characters — download PDF for full document]